Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study

Corcept Therapeutics Incorporated (CORT) announced positive data from one part of the pivotal phase III GRACE study, which evaluated its lead pipeline candidate, relacorilant, for treating patients with all etiologies of endogenous Cushing’s syndrome.The GRACE study consists of two parts. The above mentioned data was from the open-label portion of the study in which patients with Cushing’s syndrome and either hypertension, hyperglycemia or both were treated with relacorilant for a period of 22 weeks.Data fr ...